`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pharmacokinetics
`
`Michael E. Winter, Pharm.D.
`Professor of Clinical Pharmacy
`School of Pharmacy
`University of California, San Francisco
`and
`Director
`Clinical Pharmacokinefics Consultation Service
`University of California Hospitals and Clinics
`San Francisco, California
`
`Edifed b y:
`Mary Anne Koda-Kimble, PharmD.
`Professor of Cfiinical Pharmacy
`Chairwoman, Division of Clinical Pharmacy
`School of Pharmacy
`,
`University of California
`San Francisco, California
`
`Applied Therapeutics, Inc.
`Vancouver, WA
`
`
`
`
`
`Page 1
`
`SHIRE EX. 2029
`KVK v. SHIRE
`IPR2018-00290
`
`
`
`
`
`Applied Therapeutics, Inc.
`Post Office Box 5077
`
`Vancouver, Washington 98668—5077
`(206) 253—7123
`
`© Copyright 1994 by Applied Therapeutics, Inc,
`Printed in the United States of America
`
`All rights reserved No part of this book may be reproduced, stored in a retrieval system, or
`transmitted, in any form or by any means, electronic, mechanical, photocopying, recording,
`or otherwise now known or by any future method without prior written permission irom the
`publisher.
`
`
`
`
`
`
`
`Library of Congress Catalog Card Number 94-70212
`ISBN 0-915486-22—9
`
`First Printing, July 1994
`Second Printing, August 1994
`
`
`
`
`:3
`i
`
`3,
`§
`
`Page 2
`
`
`
`i229t 3 :
`
`mxmswmwm
`
`
`
`
` aioovoilobility (F)
`
`Definition
`
`Bioavailability is the percentage or fraction of the administered dose
`which reaches the systemic circulation of the patient. Examples of factors
`which can alter bioavailability include: the inherent dissolution and ab
`sorption characteristics of the administered chemical form (e.g., salt, es-
`ter), the dosage form (e.g., tablet, capsule), the route of administration,
`the stability of the active ingredient in the gastrointestinal tract, and, the
`extent of drug metabolism before reaching the systemic circulation. Drugs
`can be metabolized by gastrointestinal bacteria, by the gastrointestinal
`mucosa, and by the liver before reaching the systemic circulation.
`
`To calculate the amount of drug absorbed, the administered dose
`should be multiplied by a bioavailability factor, which is usually repre~
`sented by the letter “F.” For example, the bioavailability of digoxin (Lan—
`oxin) is estimated to be 0.7 for orally administered tablets}!2 This means
`that if 250 ug (0.25 mg) of digoxin is given orally, the effective or absorbed
`dose can be calculated by multiplying the administered dose by F:
`
`
`
`= (0.7)(250 ug)
`
`= 175 pg
`
`It should be emphasized that this factor does not take into consider
`ation the rate of drug absorption; it only estimates the extent of absorption.
`Although the rate of absorption can be important when rapid onset of
`pharmacological effects is required, it is not usually important when a
`drug is administered chronically. The rate of absorption is important only
`when it is so slow that it limits the absolute bioavailabiiity of the drug, or
`when it is so rapid that too much drug is absorbed. The former occasion-
`ally occurs with some sustained—release preparationss'd‘
`J
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dosage Form
`
`As noted earlier, bioavailability can vary among different formula-
`tions and dosage forms of a drug. For example, digoxin elixir has a bio—
`
`—2
`
`
`
`
`Page 3
`
`
`
`,7 7 ....__.7 _._ ante...
`
`.. dummies
`
`
`
`Biaavailabilitym
`
`availability of approximately 77% (F = 0.77) while the soft gelatin cap—
`sules have a bioavailability of 100% {F = 1.0). This is in contrast to the
`tablets which have a bioavailability of 70% (F : 0.7).2'5'6 When drugs are
`administered parenterally, the bioavailability is usually considered to be
`100% (F = 1.0). By rearranging Equation 1, this principle can be used to
`calculate equivalent doses of a drug when a patient is to receive a different
`dosage form of the same drug.
`
`i:..
`l;s
`
`
`
`
`
`
`
`
`
`
`
`
`
`For example, if a patient who has been receiving digoxin 250 ug
`(0.25 mg) in the tablet dosage form, needs to receive digoxin elixir instead,
`
`
`an equivalent dose of the elixir would be calculated as follows:
`
`
`
` Dose of Elixir = #35753
`
`m 227 pg
` If the soft gelatin capsules of digoxin Were to be administered, the
`bioavaflability or F of the new dosage form would have been 1.0 and the
`
`
`
`equivalent dose would have been 175 ug.
`
`
`
`
`rule. If some of the inactive precursor is excreted or eliminated from the
`body before it can be converted to the active compound, the bioavailability
`will be <1.0. For example, parenteral chloramphenicol is given as the
`
`succinate ester, and this chloramphenicol ester must be hydrolyzed to the
`active compound. The bioavailability of the parenterally—administered
`Cldoramphenicol succinate ranges from 55% to 95%, because from 5% to
`
`45% of the chloramphenicol ester is eliminated renally before it can be
`
`converted to the active compound.7
`
`
`
`
`
`Page 4
`
`
`
`
`
`Bioavaflabifity
`
` Chemical Form (8)
`
`The chemical form of a drug must aiso be considered when evaluating
`bioavailabiiity. For example, when a salt or ester of a drug is administered,
`the bioavail'ability factor (F) should be multipiied by the fraction of the _
`total molecular weight which the active drug represents. If “S” represents
`the fraction of the administered dose which is the active drug, 'then the
`amount of drug absorbed from a salt or ester form can be calculated as
`foHOWs:
`
`
`
`The "S" factor should be included in all bioavailability equations as
`a constant reminder of its importance in assessing bioavailability of the
`active drug form. When a drug is administered inits parent or active form,
`the “S" for that drug is 1.0.
`Equation 2 can now be expanded to consider the salt factor as well as
`the bioavailability when calculating the dose of a new dosage form:
`
`
`
`
`
`
`
`.
`3
`
`.
`
`1
`l1
`
`
`
`
`
`
`
`;is
`
`
`
`i
`
`Aminophyllme is an excellent example of this principle. (See Figure
`1.) Aminophyiline is the ethylenediamine salt of the pharmacologically-
`active moiety, theophylline. Eighty to eighty—five percent (by weight) of
`this salt is theophylljne, so that the “S” for arrfinophylline is approxi—
`mately 0.8. Uncoated aminophylline tablets are considered to be com-
`pletely (100%) bioavailable; the bioavailability factor (F) for this dosage
`1.0. It is important to consider the salt form in deter—
`form is, therefore,
`absorbed from an aminophylline tab—
`mining the amount of theophylline
`
`——4
`
`Page 5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Bioavailability
`
`let. When Equation 3 is applied to this situation, it can be demonstrated
`that 160 mg of theophylline is absorbed from a 200 mg aminophylline
`tablet:
`”
`
`_
`Amount of Drug. Absorbed or
`Reaching the Systemic Circulation m (SXFXDOSE)
`= (0.8)(1.0)(200 mg Aminophylline)
`
`= 160 mg Theophylline
`
`First-Pass Effect
`
`Since drugs are absorbed from the gastromtestinal tract into the portal
`circulation, some drugs may be extensively metabolized in the liver before
`reaching the systemic circulation. This ”first-pass effect” can substantially
`decrease the amount of active drug reaching the systemic circulation and
`thus, its bioavailability. (See Figure 2.)
`
`Lidocaine is an example of a drug with a first—pass effect that is so
`great that oral administration is not practical.3 In the case of propranolol
`
`
`
`*i
`
`
`
`20%
`
`EEii
`
`
`
`mewrwwmwwwmw-
`
`
`
`
`
` 200 mg Aminophyiline
`
`
`(Ethylenecliamlne Salt
`
`
`
`
`
`
`
`
`
`F
`
`of Theophyillne)
`
`Ethylenediamlne
`(40 mg)
`
`
`
`30% Whoyiline
`A
`-ime9) 9 i" '
`
`Figure l. The Efleci of the Chemical~Drug Form an Bioavailahiiity.
`The example above emphasizes the Importance of considering the
`chemical farm administered when calculating the amount of active
`drug actually administered. The amount of active drug administered
`may represent only a fraction of the salt, ester, or other chemical form
`of the drug contained In formulation. The bioavailabillty of the dosage
`form itself must also be considered when drugs are administered by the
`oral route.
`
`
`
`Page 6
`
`
`
`
`
`
`
`Bioa vailabilr‘ty 3
`
`
`
`
`
`
`
`
`40 mg
`OraEiy
`Administered
`Dru
`Q g
`
`POWG'
`
`Circulation
`
`
`
` 2mg
`
`
`
` intravenous
`
`
`
`
`Administration
`
`Figure 2. First-Pass Effect. When drugs with a high “first-pass effect"
`are administered orally. or large amount of the absorbed drug is metab—
`olized before it reaches the systemic circulation. If the drug is adminis—
`tered intravenously, the liver is bypassed and the fraction of the admin-
`istered dose that reaches the circulation is Increased. Parenteral doses
`of drugs with a “high first-pass" are much smaller than oral doses which
`produce equivalent pharmacologlc effects.
`
`
`
`
`
`
`(Inderal), a significant portion of the orally administered dose is metab~
`oljzed through a first—pass effect; therefore, a much larger oral dose is
`
`required to achieve the same pharmacologic response as that obtained
`
`from a dose administered intravenously. However, the propranolol issue
`
`is further complicated by the fact that one of the metabolites, 4-hydroxy—
`propranolol, is pharmacologicaliy active.9
`
`"—6
`
`
`
`
` unassuflswfirmw‘m
`
`
`
`
`
`Page 7
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`The administration rate is the average rate at which absorbed drug
`reaches the systemic circulation. This is usually calculated by dividing the
`amount of drug absorbed (see Equation 3) by the time over which the ‘
`drug was administered (dosing interval). The dosing interval is usually
`represented by the symbol, tau (1:).
`
`
`
`When drugs are administered as a continuous infusion, the dosing
`interval can be expressed in any convenient time unit. For example, the
`theophylline administration rate resulting from aminophylline infused at
`a rate of 75 mg/hr is calculated from Equation 5 as follows:
`
`RA
`
`E (S)(F)(Dose)
`T
`
`(0.8)(l.0)(75 mg)
`1 hr
`
`_ '
`
`60 mg/hr
`
`0"
`
`(0.8)(1.0)(75 mg)
`60 min
`
`1 mg/min
`
`
`
`
`
`
`
`Page 8
`
`
`
`
`
`Rate of Administration
`
`
`
`When drugs are administered at fixed dosing intervals, the calculateda
`administration rate is an average value. For example, the average admin-
`istration rate of the‘ophylline in mg/hr resulting from an oral dose of 300
`mg aminophylline given every six hours would be calculated using Equa-
`tion 5 as fofloWs:
`
`RA
`
`= (S)<F)<Dose)
`T
`
`_ (0.8)(1.0)(300 mg)
`‘
`6 hr
`
`= 40 mg/hr
`
`E
`§
`
`4
`
`
`
`
`
`
`
`mmwwmfimemmamwammmwu»-A....‘1..-..-_«-.im'“he-me-mm.‘.r.__.,MH___..”WA;
`
`
`
`
`
`
`
`
`yawm
`
`Page 9
`
`